BRIEF published on 04/16/2024 at 13:05, 2 years ago CureVac et MD Anderson collaborent sur des vaccins innovants contre le cancer Technologie ARNm CureVac MD Anderson Vaccins Contre Le Cancer Collaboration Biopharmaceutique
PRESS RELEASE published on 04/16/2024 at 13:00, 2 years ago CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines CureVac and MD Anderson announce strategic collaboration to develop mRNA-based cancer vaccines, leveraging respective expertise to address unmet medical needs in hematological and solid tumors Clinical Research Collaboration CureVac MD Anderson MRNA-based Cancer Vaccines
BRIEF published on 04/04/2024 at 13:05, 2 years 1 month ago CureVac Reports Positive Phase 2 Results for Influenza Vaccine in Collaboration with GSK GSK MRNA Technology CureVac Influenza Vaccine Phase 2 Trial
BRIEF published on 04/04/2024 at 13:05, 2 years 1 month ago CureVac annonce des résultats positifs de phase 2 pour son vaccin contre la grippe en collaboration avec GSK GSK Technologie ARNm CureVac Vaccin Contre La Grippe Essai De Phase 2
PRESS RELEASE published on 04/04/2024 at 13:00, 2 years 1 month ago CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK CureVac announces positive Phase 2 interim results for seasonal influenza vaccine in collaboration with GSK, showing strong antibody titers and safety profile GSK CureVac Phase 2 Seasonal Influenza Vaccine MRNA
PRESS RELEASE published on 11/01/2023 at 13:00, 2 years 6 months ago CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
PRESS RELEASE published on 09/28/2023 at 13:00, 2 years 7 months ago CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
PRESS RELEASE published on 09/12/2023 at 13:15, 2 years 8 months ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 09/12/2023 at 13:00, 2 years 8 months ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 08/17/2023 at 13:00, 2 years 8 months ago CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Published on 05/13/2026 at 00:00, 6 hours 7 minutes ago Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 6 hours 32 minutes ago Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 8 hours 12 minutes ago UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/12/2026 at 21:42, 8 hours 25 minutes ago Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026
Published on 05/13/2026 at 04:00, 2 hours 7 minutes ago Siam Piwat redefines global retail with NEXTOPIA, a future prototype where sustainability is a transformative force for business, people, and the planet
Published on 05/12/2026 at 23:47, 6 hours 20 minutes ago Nebius welcomes Clarifai’s core team and licenses inference IP to strengthen Nebius Token Factory
Published on 05/12/2026 at 22:25, 7 hours 42 minutes ago Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Published on 05/12/2026 at 20:21, 9 hours 46 minutes ago Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 10 hours 32 minutes ago AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 18:15, 11 hours 52 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 11 hours 52 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 11 hours 57 minutes ago imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 11 hours 57 minutes ago imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 12 hours 17 minutes ago Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités
